» Articles » PMID: 34027514

Post-COVID Syndrome in Non-hospitalised Patients with COVID-19: a Longitudinal Prospective Cohort Study

Abstract

Background: While the leading symptoms during coronavirus disease 2019 (COVID-19) are acute and the majority of patients fully recover, a significant fraction of patients now increasingly experience long-term health consequences. However, most data available focus on health-related events after severe infection and hospitalisation. We present a longitudinal, prospective analysis of health consequences in patients who initially presented with no or minor symptoms of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection. Hence, we focus on mild COVID-19 in non-hospitalised patients.

Methods: 958 Patients with confirmed SARS-CoV-2 infection were observed from April 6th to December 2nd 2020 for long-term symptoms and SARS-CoV-2 antibodies. We identified anosmia, ageusia, fatigue or shortness of breath as most common, persisting symptoms at month 4 and 7 and summarised presence of such long-term health consequences as post-COVID syndrome (PCS). Predictors of long-term symptoms were assessed using an uni- and multivariable logistic regression model.

Findings: We observed 442 and 353 patients over four and seven months after symptom onset, respectively. Four months post SARS-CoV-2 infection, 8•6% (38/442) of patients presented with shortness of breath, 12•4% (55/442) with anosmia, 11•1% (49/442) with ageusia and 9•7% (43/442) with fatigue. At least one of these characteristic symptoms was present in 27•8% (123/442) and 34•8% (123/353) at month 4 and 7 post-infection, respectively. A lower baseline level of SARS-CoV-2 IgG, anosmia and diarrhoea during acute COVID-19 were associated with higher risk to develop long-term symptoms.

Interpretation: The on-going presence of either shortness of breath, anosmia, ageusia or fatigue as long-lasting symptoms even in non-hospitalised patients was observed at four and seven months post-infection and summarised as post-COVID syndrome (PCS). The continued assessment of patients with PCS will become a major task to define and mitigate the socioeconomic and medical long-term effects of COVID-19.

Funding: COVIM:"NaFoUniMedCovid19"(FKZ: 01KX2021).

Citing Articles

NETosis: A key player in autoimmunity, COVID-19, and long COVID.

Monsalve D, Acosta-Ampudia Y, Acosta N, Celis-Andrade M, Sahin A, Yilmaz A J Transl Autoimmun. 2025; 10:100280.

PMID: 40071133 PMC: 11894324. DOI: 10.1016/j.jtauto.2025.100280.


Myocardial Dysfunction and Risk of Long COVID in Patients Recovered From Mild and Moderate COVID-19.

Zhou B, Zhang Y, Han S, Zhang J, Song L, Wang H Echocardiography. 2025; 42(3):e70120.

PMID: 40029146 PMC: 11875044. DOI: 10.1111/echo.70120.


Circulating Autoantibodies Against Vasoactive Biomarkers Related to Orthostatic Intolerance in Long COVID Patients Compared to No-Long-COVID Populations: A Case-Control Study.

Han E, Muller-Zlabinger K, Hasimbegovic E, Poschenreithner L, Kastner N, Maleiner B Biomolecules. 2025; 15(2).

PMID: 40001603 PMC: 11853648. DOI: 10.3390/biom15020300.


Identification of a multi-omics factor predictive of long COVID in the IMPACC study.

Gabernet G, Maciuch J, Gygi J, Moore J, Hoch A, Syphurs C bioRxiv. 2025; .

PMID: 39990442 PMC: 11844572. DOI: 10.1101/2025.02.12.637926.


Demographic, epidemiological and clinical profile of patients with post-COVID syndrome followed at a teaching hospital in Brazil.

Melo J, Silva A, Yamamoto L, Ferreira T, Luvizutto G, Neves F Braz J Infect Dis. 2025; 29(2):104509.

PMID: 39978115 PMC: 11889545. DOI: 10.1016/j.bjid.2025.104509.


References
1.
Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View

2.
Patanavanich R, Glantz S . Smoking is associated with worse outcomes of COVID-19 particularly among younger adults: a systematic review and meta-analysis. BMC Public Health. 2021; 21(1):1554. PMC: 8366155. DOI: 10.1186/s12889-021-11579-x. View

3.
Sze S, Pan D, Nevill C, Gray L, Martin C, Nazareth J . Ethnicity and clinical outcomes in COVID-19: A systematic review and meta-analysis. EClinicalMedicine. 2020; 29:100630. PMC: 7658622. DOI: 10.1016/j.eclinm.2020.100630. View

4.
Lee Y, Min P, Lee S, Kim S . Prevalence and Duration of Acute Loss of Smell or Taste in COVID-19 Patients. J Korean Med Sci. 2020; 35(18):e174. PMC: 7211515. DOI: 10.3346/jkms.2020.35.e174. View

5.
Lechien J, Chiesa-Estomba C, De Siati D, Horoi M, Le Bon S, Rodriguez A . Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020; 277(8):2251-2261. PMC: 7134551. DOI: 10.1007/s00405-020-05965-1. View